Preferred Label : Technology Assessment;
NCIt definition : Technology assessment (TA) arose in the mid-1960s from an appreciation of the critical
role of technology in modern society and its potential for unintended, and sometimes
harmful, consequences. TA was conceived as a way to identify the desirable first-order,
intended effects of technologies as well as the higher-order, unintended social, economic
and environmental effects. TA methodology draws upon a variety of analytical, evaluative
and planning techniques. Among these are systems analysis, cost-benefit analysis,
consensus methods (e.g., Delphi method), engineering feasibility studies, clinical
trials, market research, technological forecasting, and others. TA practitioners and
policy makers recognized that TA is evolving, flexible, and should be tailored to
the task (Brooks and Bowers 1970 and U.S. Congress, Office of Technology Assessment
1977).;
Origin ID : C15335;
UMLS CUI : C0039422;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
Semantic type(s)
UMLS correspondences (same concept)
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/evaluation-des-technologies-de-reduction-des-agents-pathogenes-interceptmc-et-mirasolmc-pour-le-traitement-des-produits-sanguins-labiles-au-quebec.html
2023
Canada
health technology assessment
Technology Assessment
Helianthus annuus
Blood Treatment
reducing agents
Blood Product
Pathogen
quebec
technology assessment
Reducing Excipient
technology assessment, biomedical
Intercept
---
https://www.has-sante.fr/jcms/p_3471037/fr/actualisation-2023-utilite-clinique-des-signatures-genomiques-dans-le-cancer-du-sein-rh-/her2-de-stade-precoce
2023
France
health technology assessment
neoplasm staging
Clinical Batch
Medical Examination
early
genome
breast cancer
Clinical Lot
technology assessment
genomics
Early Stage Breast Carcinoma
Genome
Clinical Data
hospitals, proprietary
health
Ambulatory Care Facility
Technology Assessment
neoplasm, malignant
genome, nos
technology assessment, biomedical
breast neoplasms
Signature
Useful
---